Key result
Pharmacogenetic-guided medication review is linked to ~38% more identified medication change opportunities.
Why the study?
Polypharmacy in long-term care residents is common and associated with increased costs and adverse events, motivating evaluation of pharmacogenetic testing to optimize medication management.
Does pharmacogenetic-guided medication review increase medication change opportunities and reduce costs in long-term care facility residents with polypharmacy?
Observational (n=112)
Yes
Does pharmacogenetic-guided medication review increase medication change opportunities and reduce costs in long-term care facility residents with polypharmacy?
Adding pharmacogenetic testing to traditional medication review in long-term care residents with polypharmacy increases opportunities for regimen optimization and may yield significant cost savings.
Answers are grounded in this paper and cite their sources.
May aid regimen optimization in long-term care polypharmacy; leaves open prospective RCTs on outcomes and costs.
BACKGROUND: Among long-term care facility residents, polypharmacy is common, and often appropriate, given the need to treat multiple, complex, chronic conditions. Polypharmacy has, however, been associated with increased healthcare costs, adverse drug events, and drug interactions. The current study evaluates the potential medication cost savings of adding personalized pharmacogenetic information to traditional medication management strategies. METHODS: test results, an internal medication management assessment was performed by a licensed clinical pharmacist to identify potential opportunities for regimen optimization through medication changes or discontinuations. The medication cost differences before and after the pharmacogenetic-guided review were assessed. RESULTS: Medication review following pharmacogenetic result reporting identified 54 patients (48.2%) with a total of 132 drug change recommendations (45 reductions; 87 replacements) and an average of 2.4 proposed medication changes (range 1-6) per patient. Medication cost savings related to the identified reduction and replacement opportunities exceeded the cost of testing and are estimated to be US$ 1300 (year 2016 cost) per patient annually assuming full implementation. CONCLUSION: Compared with traditional medication review, pharmacogenetic testing resulted in a 38% increase in the number of patients with current medication change opportunities and also offered valuable genetic information that could be referenced to personalize future prescribing decisions for all patients.
No takes yet. Share an insight, caveat, or question.
Sugarman et al. (2016) conducted an observational in Polypharmacy (n=112). Pharmacogenetic testing (IDgenetix Polypharmacy test) vs. Traditional medication review was evaluated on Patients identified with medication change opportunities. Pharmacogenetic testing added to medication review increased the identification of patients with medication change opportunities by 38%, with estimated annual drug cost savings of $1300 per patient.
Synapse has enriched 10 related papers. Consider them for comparative context: